2020
DOI: 10.1177/0003134820950298
|View full text |Cite
|
Sign up to set email alerts
|

What Is the Utility of Restaging Imaging for Patients With Clinical Stage II/III Rectal Cancer After Completion of Neoadjuvant Chemoradiation and Prior to Proctectomy?

Abstract: Background In the United States, patients with clinical stage II or III rectal cancer typically receive neoadjuvant chemoradiation therapy (chemo/XRT) over a 5-6 week period followed by a 6-10 week break prior to proctectomy. In the current study, we evaluate the utilization of restaging studies performed and detection of disease progression during this window. Methods A retrospective review of patients with clinical stage II/III rectal cancer was performed. Medical records were analyzed to collect clinicopath… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2021
2021
2021
2021

Publication Types

Select...
1

Relationship

0
1

Authors

Journals

citations
Cited by 1 publication
(1 citation statement)
references
References 16 publications
0
1
0
Order By: Relevance
“…Recently, some studies have shown that the predictive power of post-nCRT variables may be better than those of pre-nCRT variables, meaning that post-nCRT clinical or imaging features could provide more valuable information regarding the response to nCRT ( 23 27 ). Moreover, restaging with PET/CT could even detect new metastatic lesions after long-course nCRT in some patients with non-pCR ( 25 ).…”
Section: Discussionmentioning
confidence: 99%
“…Recently, some studies have shown that the predictive power of post-nCRT variables may be better than those of pre-nCRT variables, meaning that post-nCRT clinical or imaging features could provide more valuable information regarding the response to nCRT ( 23 27 ). Moreover, restaging with PET/CT could even detect new metastatic lesions after long-course nCRT in some patients with non-pCR ( 25 ).…”
Section: Discussionmentioning
confidence: 99%